Your session is about to expire
← Back to Search
BI 685509 for Diabetic Kidney Disease
Study Summary
This trial is testing whether BI 685509 improves kidney function in adults with diabetic kidney disease. Participants are assigned to one of three doses of BI 685509 or placebo by chance, and take the medication 3 times a day for 7 months. Urine samples are collected throughout to assess kidney function, and the results are compared between groups at the end.
- Diabetic Kidney Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are researchers still looking for participants in this clinical trial?
"According to the most recent update on clinicaltrials.gov, this particular trial is not looking for new patients at the moment. This study was first brought to public attention on April 27th 2021 and had its last update November 15th 2022. Although this research isn't searching for volunteers right now, there are 502 other trials that are currently looking for participants."
Is this trial taking place in many hospitals across America?
"There are 26 enrolling patients for this clinical trial. For example, Meridian Clinical Research, LLC in Norfolk, Kidney and Hypertension Center in Victorville, and DaVita Clinical Research in Houston offer this study. In total, there are 26 other locations where this research is being conducted."
What is the FDA's stance on BI 685509?
"While Phase 2 trials don't have the same level of data to support efficacy, BI 685509 received a score of 2 for safety because there is some clinical evidence."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
What site did they apply to?
Share this study with friends
Copy Link
Messenger